These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30642440)

  • 1. Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor.
    Mai S; Xiong G; Diao D; Wang W; Zhou Y; Cai R
    Lung Cancer; 2019 Feb; 128():101-104. PubMed ID: 30642440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
    BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.
    Hornick JL; Sholl LM; Dal Cin P; Childress MA; Lovly CM
    Mod Pathol; 2015 May; 28(5):732-9. PubMed ID: 25612511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
    Morris TA; Khoo C; Solomon BJ
    Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
    Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
    Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
    Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
    Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature.
    Korkmaz M; Eryilmaz MK
    Anticancer Drugs; 2022 Jan; 33(1):e799-e801. PubMed ID: 34459458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
    Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
    Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deepening the Knowledge of
    Guaitoli G; Bertolini F; Bettelli S; Manfredini S; Maur M; Trudu L; Aramini B; Masciale V; Grisendi G; Dominici M; Barbieri F
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884672
    [No Abstract]   [Full Text] [Related]  

  • 11. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib.
    Ju L; Han M; Su J; Wu C; Dong Z
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):561-564. PubMed ID: 30083883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report.
    Wu S; Liu K; Ren F; Zheng D; Pan D
    BMC Pulm Med; 2018 Jul; 18(1):121. PubMed ID: 30029601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
    Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
    Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.
    Dong L; Xia J; Zhang J; Zhang Y; Zhu N; Zhang P; Zhang Y; Zhang X; Li S
    BMC Pulm Med; 2018 Jan; 18(1):13. PubMed ID: 29361925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.